Literature DB >> 1708114

The relationship between ventral striatal efferent fibers and the distribution of peptide-positive woolly fibers in the forebrain of the rhesus monkey.

S N Haber1, D P Wolfe, H J Groenewegen.   

Abstract

Peptidergic fibers in the globus pallidus of the monkey appear in the morphological form referred to as woolly fibers. These fibers are composed of a dense plexus of thin beaded axons which ensheath an unstained central core. Such structures are not confined to the globus pallidus, but are also present in the bed nucleus of the stria terminalis, the hypothalamus, the dorsal part of the amygdala, and ventrally in the basal forebrain. The present study describes the relationship between projections from the rostral and ventral striatum and the enkephalin- and substance P-positive woolly fibers. Following injections of either tritiated amino acids or the lectin Phaseolus vulgaris-leucoagglutinin in the ventral striatum, anterogradely labeled fibers and terminals in the forebrain were visualized simultaneously with enkephalin- or substance P immunoreactivity in the same tissue section in order to determine: (i) the extent to which the woolly fiber distribution represents striatal output systems; (ii) whether woolly fibers can be considered as a marker for the entire striatal forebrain projection; and (iii) whether enkephalin and substance P are involved differentially in distinct ventral striatopallidal pathways. Phaseolus vulgaris-leucoagglutinin labeling is seen in the globus pallidus and adjacent structures either as single, beaded fibers or in a profile strikingly similar to that of woolly fibers. In tissue sections treated for a double immunohistochemical protocol, following which the Phaseolus vulgaris-leucoagglutinin-immunoreactive fibers turn black and the peptidergic woolly fibers brown; many of the lectin-positive fibers are seen to enter the peptide-positive woolly fiber plexus. Likewise, following the injections with tritiated amino acids in the ventral striatum, coarse structures that have dimensions resembling those of the woolly fibers are identified. In sections immunohistochemically stained and subsequently treated for autoradiography, peptide-positive woolly fibers can be identified underlying the silver grains. In sections stained for both peptide immunoreactivity and tracer substances, enkephalin or substance P-positive woolly fibers are present in all pallidal regions that receive ventral striatal input. However, the ventral striatum also sends fibers to the hypothalamus, bed nucleus of the stria terminalis, the dorsal part of the amygdala, the septum, the preoptic area, and other areas of the basal forebrain. In these nuclei the peptide-positive woolly fiber distribution is less extensive than the terminal labeling. The distribution of substance P-positive fibers in the subcommissural pallidal region is more limited than the distribution of enkephalinergic fibers.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1708114     DOI: 10.1016/0306-4522(90)90271-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  10 in total

Review 1.  The ventral pallidum: Subregion-specific functional anatomy and roles in motivated behaviors.

Authors:  David H Root; Roberto I Melendez; Laszlo Zaborszky; T Celeste Napier
Journal:  Prog Neurobiol       Date:  2015-04-06       Impact factor: 11.685

Review 2.  The reward circuit: linking primate anatomy and human imaging.

Authors:  Suzanne N Haber; Brian Knutson
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

3.  Neurochemical heterogeneity of the primate nucleus accumbens.

Authors:  K Ikemoto; K Satoh; T Maeda; H C Fibiger
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

4.  The globus pallidus sends reward-related signals to the lateral habenula.

Authors:  Simon Hong; Okihide Hikosaka
Journal:  Neuron       Date:  2008-11-26       Impact factor: 17.173

5.  Nucleus accumbens high-frequency stimulation selectively impacts nigrostriatal dopaminergic neurons.

Authors:  Thibaut Sesia; Brandon Bizup; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2013-10-17       Impact factor: 5.176

6.  The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.

Authors:  P Suchankova; J Yan; M L Schwandt; B L Stangl; E C Caparelli; R Momenan; E Jerlhag; J A Engel; C A Hodgkinson; M Egli; M F Lopez; H C Becker; D Goldman; M Heilig; V A Ramchandani; L Leggio
Journal:  Transl Psychiatry       Date:  2015-06-16       Impact factor: 6.222

7.  Automatic target validation based on neuroscientific literature mining for tractography.

Authors:  Xavier Vasques; Renaud Richardet; Sean L Hill; David Slater; Jean-Cedric Chappelier; Etienne Pralong; Jocelyne Bloch; Bogdan Draganski; Laura Cif
Journal:  Front Neuroanat       Date:  2015-05-27       Impact factor: 3.856

8.  An improved neuroanatomical model of the default-mode network reconciles previous neuroimaging and neuropathological findings.

Authors:  Pedro Nascimento Alves; Chris Foulon; Vyacheslav Karolis; Danilo Bzdok; Daniel S Margulies; Emmanuelle Volle; Michel Thiebaut de Schotten
Journal:  Commun Biol       Date:  2019-10-10

9.  Mesencephalic dopamine neurons interfacing the shell of nucleus accumbens and the dorsolateral striatum in the rat.

Authors:  Floris G Wouterlood; Angela Engel; Mariah Daal; Gertjan Houwen; Aileen Meinderts; Tomàs Jordà Siquier; Jeroen A M Beliën; Yvette C van Dongen; Jørgen Scheel-Krüger; Anne-Marie Thierry; Henk J Groenewegen; Jean-Michel Deniau
Journal:  J Neurosci Res       Date:  2018-04-25       Impact factor: 4.164

10.  The Response of Ventral Tegmental Area Dopaminergic Neurons to Bupropion: Excitation or Inhibition?

Authors:  Shirin Sadighparvar; Fereshteh Tale; Parviz Shahabi; Somayyeh Naderi; Firouz Ghaderi Pakdel
Journal:  Basic Clin Neurosci       Date:  2019-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.